Lung Cancer - Non-Small Cell News

Share

Lung Cancer - Non-Small Cell News


Ceritinib Highly Active in Advanced ALK-Positive NSCLC (April 1, 2014)

The investigational compound ceritinib (LDK378) was highly active in patients with advanced ALK-positive non-small cell lung cancer, according to the results of a study published in the New England Journal... Continue Reading

Nintedanib Plus Docetaxel is Effective Second-Line Therapy for NSCLC (March 6, 2014)

Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced non-small cell lung cancer previously treated with one line of platinum-based therapy, according to... Continue Reading

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis (December 26, 2013)

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among... Continue Reading

Novel ALK-Inhibitor Active in NSCLC with Brain Metastasis (December 18, 2013)

The novel targeted agent AP26113 shows strong anti-tumor activity in Xalkori® (crizotinib)-resistant and Xalkori-naïve patients with non-small cell lung cancer, including those with brain metastasis... Continue Reading

Marriage May Have a Protective Effect for Cancer Patients (December 17, 2013)

Social support may have a significant impact on cancer detection, treatment, and survival, according to the results of a study published in the Journal of Clinical Oncology. The study showed that married... Continue Reading

National Lung Cancer Awareness Month on CancerConnect (November 14, 2013)

November 14, 2014 Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of lung cancer programs for national lung cancer awareness month. As the month of November brings lung... Continue Reading

End-of-Life Care Remains Aggressive, Despite Patient Wishes (September 16, 2013)

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact,... Continue Reading

USPSTF Recommends Lung Cancer Screening in High-Risk Individuals (August 23, 2013)

The U.S. Preventive Services Task Force (USPSTF) recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancer-related... Continue Reading

Gilotrif Approved for Metastatic EGFR-Positive NSCLC (July 26, 2013)

The U.S. Food and Drug Administration (FDA) has approved Gilotrif™ (afatinib) for the treatment of metastatic non-small cell lung tumors that express specific types of epidermal growth factor receptor... Continue Reading

Dr. Jackman from Dana-Farber Provides Guest Moderation in CancerConnect Lung Cancer Community (June 27, 2013)

CancerConnect partnered with Dana-Farber Cancer Institute to provide you with the opportunity to engage with a lung cancer expert, David M. Jackman, MD, who answered questions and relayed important information... Continue Reading

More Lung Cancer - Non-Small Cell News

Latest Lung Cancer - Non-Small Cell News By Stage


Screening/Prevention

Lung Cancer Screening with Low-Dose CT Scan May Lead to Overdiagnosis (December 26, 2013)

Screening for lung cancer with low-dose CT scan may lead to overdiagnosis, according to the results of a study published in JAMA Internal Medicine. Lung cancer is the leading cause of cancer death among both men and women in the United States. The disease... Continue Reading

National Lung Cancer Awareness Month on CancerConnect (November 14, 2013)

November 14, 2014 Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of lung cancer programs for national lung cancer awareness month. As the month of November brings lung cancer into focus, it’s time to increase public... Continue Reading

USPSTF Recommends Lung Cancer Screening in High-Risk Individuals (August 23, 2013)

The U.S. Preventive Services Task Force (USPSTF) recommends screening people who are at high risk for lung cancer with annual low-dose CT scans, which can prevent a substantial number of lung cancer-related deaths. This is a grade B draft recommendation. Lung... Continue Reading

Screening Could Reduce Lung Cancer Mortality (April 24, 2013)

Screening for lung cancer with low-dose computed tomography (LDCT) in all screening-eligible current and former smokers could potentially avert approximately 12,000 lung cancer deaths each year in the United States, according to the results of a study... Continue Reading

Hormone Replacement Therapy in Newly Menopausal Women May Carry More Benefit Than Risk (October 26, 2012)

Hormone replacement therapy for newly menopausal women may not be as risky as once believed, according to the results of a study presented at the 23rd annual meeting of the North American Menopause Society in Orlando, Florida in October 2012.[1] In fact,... Continue Reading

More Screening/Prevention Lung Cancer - Non-Small Cell

Stages I-IIIA

National Lung Cancer Awareness Month on CancerConnect (November 14, 2013)

November 14, 2014 Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of lung cancer programs for national lung cancer awareness month. As the month of November brings lung cancer into focus, it’s time to increase public... Continue Reading

Standard Dose of Radiation Therapy Outperforms Higher Dose for Advanced Non-Small Cell Lung Cancer (June 12, 2013)

In a phase III clinical trial, a standard dose of radiation therapy was more effective than a higher dose for the treatment of stage III non-small cell lung cancer (NSCLC). These results will be presented at the 49th Annual Meeting of the American Society... Continue Reading

Stereotactic Body Radiation Improves Lung Cancer Survival (November 9, 2012)

Stereotactic body radiation for early-stage, inoperable non-small cell lung cancer yields high overall survival rates and low toxicity compared to conventional radiotherapy, according to the results of a study presented at the annual meeting of the American... Continue Reading

Genetic Study Identifies New Targets for Treating Squamous Cell Lung Cancer (September 19, 2012)

Researchers have identified a large variety of genetic alterations that appear to be responsible for the development and growth of squamous cell lung cancer, according to the results of a study published in Nature. The discovery could lead to new targeted... Continue Reading

Overall Health, Not Just Age, is an Important Factor in Treatment of Non-Small Cell Lung Cancer (May 14, 2012)

Younger patients with non-small cell lung cancer (NSCLC) are more likely to receive treatment than older patients, regardless of overall health and prognosis, according to the results of a study published in the Journal of Clinical Oncology. Lung cancer... Continue Reading

More Stages I-IIIA Lung Cancer - Non-Small Cell

Stages IIIB-IV

Ceritinib Highly Active in Advanced ALK-Positive NSCLC (April 1, 2014)

The investigational compound ceritinib (LDK378) was highly active in patients with advanced ALK-positive non-small cell lung cancer, according to the results of a study published in the New England Journal of Medicine. Lung cancer is the leading cause... Continue Reading

Nintedanib Plus Docetaxel is Effective Second-Line Therapy for NSCLC (March 6, 2014)

Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced non-small cell lung cancer previously treated with one line of platinum-based therapy, according to the results of a study published in The Lancet Oncology. Lung... Continue Reading

Novel ALK-Inhibitor Active in NSCLC with Brain Metastasis (December 18, 2013)

The novel targeted agent AP26113 shows strong anti-tumor activity in Xalkori® (crizotinib)-resistant and Xalkori-naïve patients with non-small cell lung cancer, including those with brain metastasis after treatment with Xalkori. Lung cancer is the leading... Continue Reading

National Lung Cancer Awareness Month on CancerConnect (November 14, 2013)

November 14, 2014 Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of lung cancer programs for national lung cancer awareness month. As the month of November brings lung cancer into focus, it’s time to increase public... Continue Reading

Gilotrif Approved for Metastatic EGFR-Positive NSCLC (July 26, 2013)

The U.S. Food and Drug Administration (FDA) has approved Gilotrif™ (afatinib) for the treatment of metastatic non-small cell lung tumors that express specific types of epidermal growth factor receptor (EGFR) gene mutations. Lung cancer remains the leading... Continue Reading

More Stages IIIB-IV Lung Cancer - Non-Small Cell

Recurrent

Ceritinib Highly Active in Advanced ALK-Positive NSCLC (April 1, 2014)

The investigational compound ceritinib (LDK378) was highly active in patients with advanced ALK-positive non-small cell lung cancer, according to the results of a study published in the New England Journal of Medicine. Lung cancer is the leading cause... Continue Reading

Nintedanib Plus Docetaxel is Effective Second-Line Therapy for NSCLC (March 6, 2014)

Nintedanib in combination with docetaxel is an effective second-line option for patients with advanced non-small cell lung cancer previously treated with one line of platinum-based therapy, according to the results of a study published in The Lancet Oncology. Lung... Continue Reading

Novel ALK-Inhibitor Active in NSCLC with Brain Metastasis (December 18, 2013)

The novel targeted agent AP26113 shows strong anti-tumor activity in Xalkori® (crizotinib)-resistant and Xalkori-naïve patients with non-small cell lung cancer, including those with brain metastasis after treatment with Xalkori. Lung cancer is the leading... Continue Reading

National Lung Cancer Awareness Month on CancerConnect (November 14, 2013)

November 14, 2014 Sun Valley, ID & Fort Worth, TX—OMNI Health Media (OMNI) announces the launch of lung cancer programs for national lung cancer awareness month. As the month of November brings lung cancer into focus, it’s time to increase public... Continue Reading

Gilotrif Approved for Metastatic EGFR-Positive NSCLC (July 26, 2013)

The U.S. Food and Drug Administration (FDA) has approved Gilotrif™ (afatinib) for the treatment of metastatic non-small cell lung tumors that express specific types of epidermal growth factor receptor (EGFR) gene mutations. Lung cancer remains the leading... Continue Reading

More Recurrent Lung Cancer - Non-Small Cell

CancerConnect Cancer Commuity & Discussions


Cancer Types

Sign up for the CancerConnect newsletter

Sign up for our newsletter and receive the latest news and updates about specific types of cancer.

  Close |  Please don't show me this again

Just another WordPress weblog
Facebook Twitter RSS